Critical Deadline Approaches for Investors of ImmunityBio's Securities Fraud Case

Important Update for ImmunityBio Investors

ImmunityBio, Inc. (NASDAQ: IBRX) is currently facing a securities fraud class action lawsuit filed on behalf of investors who purchased or acquired securities from January 19, 2026, to March 24, 2026. The case is officially known as Douglas v. ImmunityBio, Inc., filed in the United States District Court for the Central District of California.

Key Details of the Class Action

The lawsuit claims that ImmunityBio made materially false statements regarding its lead biologic product, Anktiva. Investors are primarily concerned with allegations that the company misrepresented the drug's capabilities—claiming it could cure and prevent cancer—while failing to disclose crucial information about its operational status and potential risks.

The deadline for potential lead plaintiffs to file for court representation is May 26, 2026. Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP, a recognized law firm specializing in securities litigation, for better understanding and to discuss their legal options.

If you're an investor affected by the decline in IBRX's stock price, which plummeted by 21.12% following a critical FDA warning on March 24, it's vital to act now to protect your rights.

Why Did IBRX's Stock Drop?

The sharp decline in ImmunityBio's stock was linked to revelations from Bloomberg reporting on a warning from the FDA regarding misleading statements made by Patrick Soon-Shiong, the Executive Chairman. The FDA criticized a podcast where Soon-Shiong claimed that Anktiva could cure all forms of cancer. Following this disclosure, shares of ImmunityBio fell significantly, closing at $7.42 on the day of the announcement.

Investors who acquired shares during the class period may be eligible to recover losses by participating in the lawsuit. However, it’s important to note that involvement as a lead plaintiff is only necessary for those who wish to take a more active role in the litigation process.

Next Steps for Investors

1. Deadline Awareness: Keep in mind the May 26 deadline if you wish to pursue lead plaintiff status.
2. Contact Legal Counsel: Investors are encouraged to reach out to Jonathan Naji, Esq. at Kessler Topaz for a free consultation to discuss individual circumstances and options moving forward. The communication can be accomplished without any cost obligations.
3. Stay Informed: Understanding your rights and the details of the ongoing litigation process is crucial. Kessler Topaz provides resources to assist investors in comprehending the evolving situation.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz is a reputable law firm with a strong track record in handling securities fraud cases, representing a range of clients from individual investors to large institutions. They have successfully recovered billions for clients and are recognized for their commitment to investor protection.

The firm emphasizes that participation in this class action does not incur costs unless they successfully recover losses. Interested parties should urgently initiate contact to ensure they meet all necessary legal timelines and safeguard their economic interests regarding their investment in ImmunityBio, Inc.

For additional inquiries related to this case or specifics on how to engage with their legal team, please visit Kessler Topaz Meltzer & Check's website or call directly to discuss further.

In conclusion, the circumstances surrounding ImmunityBio remind investors of the imperative need for diligence and prompt action in potential securities fraud scenarios. Don’t miss the opportunity to make your voice heard in the legal proceedings that could impact your financial future significantly.